Thymic carcinoma (TC) is a rare cancer whose genomic features have been examined in only a limited number of patients of European descent. Here, we characterized both genomic and epigenomic aberrations by whole exome sequencing, RNA sequencing, methylation array and copy number analyses in TCs from Asian patients and compared them with those in TCs from USA/European patients. Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue. All 10 cases were Japanese patients treated at the National Cancer Center Hospital, Japan, between 1994 and 2010. Mutational signature analysis indicated that the accumulation of age-related mutations drive TC development. We identified recurrent somatic mutations in TET2, CYLD, SETD2, TP53, FBXW7, HRAS and RB1, and no mutations in GTF2I, supporting the hypothesis that TC and thymoma are distinguishable by their genetic profiles. TCs with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression. Focal genome copy number gains, associated with elevated gene expression, were observed at the KIT (which is known to drive thymic carcinogenesis) and AHNAK2 gene loci. Taken together, the results suggest that the molecular processes leading to TC depend on the accumulation of genetic and epigenetic aberrations. In addition, epigenetic dysregulation as a result of the TET2 mutation was observed in a subset of TCs.
Introduction
Thymic carcinoma (TC) is rare; however, it is the most aggressive type of thymic epithelial tumor (1) . Because of its low incidence, exogenous and endogenous risk factors for the development of TCs, with potential for translation to prevention strategies, are largely unknown. Although complete surgical resection is the most effective curative treatment for TC, almost 30% of patients suffer from local invasion or metastasis (2) . Patients with recurrent or advanced TC are primarily treated with cisplatin-based chemotherapy; however, this approach is not particularly effective. In contrast, patients with TCs, whose tumors are positive for activating KIT mutations and who are treated with imatinib (a tyrosine kinase inhibitor effective against KIT), demonstrate dramatic therapeutic responses (3) . Therefore, additional information regarding the genetic and epigenetic changes associated with TC has the potential to facilitate improvements in the prevention and treatment of this disease.
A recent report of comprehensive genomic and transcriptomic analysis of TCs from 16 patients of European descent indicated that the genomic profile of TC is different from that of thymoma, which is associated with frequent (80%) somatic mutation of the GTF2I gene (4) . That study, together with a subsequent targeted sequencing analysis, revealed a set of cancerrelated genes that are recurrently mutated in TC, including TP53, CYLD, CDKN2A, TET2 and BAP1 (4, 5) . In addition, a small subset (<10%) of TCs have activating mutations in KIT or EGFR (6, 7) . However, there is a dearth of information about the global aspects of TC genetic profiles, including mutation signatures representing carcinogenic processes, epigenetic aberrations and differences between Caucasians and Asians. Here, we performed multiple omics analysis, consisting of whole exome sequencing, RNA sequencing, methylation array and copy number analyses, of TCs from 10 Asian patients. The results revealed not only the similarity of genomic aberrations in Asian and Caucasian patients but also genetic and epigenetic features that contribute to our understanding of the molecular mechanisms underlying TC development.
Patients and methods

Patients
All tumors and corresponding non-cancerous tissue specimens were obtained during surgery or autopsy from patients with TCs between 1994 and 2010 and snap-frozen. All patients were Japanese and were treated in the National Cancer Center Hospital, Tokyo, Japan (Table 1) . Information regarding age, gender, race, clinical stage (Masaoka classification) and treatment record were collected retrospectively. The study was approved by the Institutional Review Boards of the National Cancer Center, Japan.
Exome sequencing
Exome sequencing was conducted using 2.5 μg DNA isolated from snapfrozen cancerous or non-cancerous (thymic) tissues as described previously (8) . Exome capture was performed using the Agilent SureSelect Human All Exon V5 kit, according to the manufacturer's instructions. Exome sequencing was performed on the Illumina HiSeq 2000 platform using 75 bp paired-end reads (Illumina, San Diego, CA, USA). Basic alignment and sequence quality control were conducted using the Picard and Firehose pipelines. Sequence reads were aligned against the UCSC human reference genome (human genome 19) using the Burrows Wheeler Aligner Multi-Vision software package. Since duplicate reads were generated during the PCR amplification process, paired-end reads that aligned to the same genomic positions were removed using SAMtools.
Somatic single-nucleotide variations were called using the MuTect program, which applies a Bayesian classifier to allow the detection of somatic mutations with low allele frequencies (9) . Somatic insertion/deletion mutations were called by the GATK Somatic Indel Detector (BROAD Institute, http://www.broadinstitute.org/gatk/). Single-nucleotide variation and insertion/deletion detection was supported by visual examination using Integrative Genomics Viewer software (BROAD Institute, http:// www.broadinstitute.org/igv/).
Analysis of mutational signature
Mutational signatures of TC genome were decomposed by the deconstrucSigs software (10) in which multiple regression approach was used to extract signatures based on those in Catalogue of Somatic Mutations in Cancer (COSMIC, http://cancer.sanger.ac.uk/cosmic/signatures) and to statistically quantify the contribution of each signature for each tumor.
Hierarchical Clustering based on signature profiles was performed using R command hclust.
Genome copy number analysis and tumor content estimation
Genome copy number and allelic status were assessed in all study cases by Illumina OMNI 2.5M array analysis, according to manufacturer's instructions, as described previously (8) . Genome copy numbers were deduced using the Global Parameter Hidden Markov Model (GPHMM) method (11) . Focal copy number alterations were detected as regions with copy numbers altered compared with those of the chromosome arms that they mapped to.
Whole transcriptome sequencing
A TruSeq RNA Sample Prep Kit (Illumina) was used to prepare RNA sequencing libraries from 1 µg total RNA. The resulting libraries were subjected to paired-end sequencing of 75 bp reads on a HiSeq 2000 (Illumina). Fusion transcripts were detected using the TopHat-Fusion algorithm (12) . This analysis was performed in all study cases other than TH13-015 and TH14-001, for which RNA samples of sufficient quality were not available. The fusion transcripts were validated using reverse transcription (RT)-PCR and Sanger sequencing, as described previously (13) . FPKM (fragments per kilobase of exon per million fragments mapped) values were available for eight cases, i.e. TET2 mutation-positive (n = 3) and mutation-negative (n = 5) tumors, and two non-tumor thymic tissues. The subtracted FPKM value of each tumor was calculated by subtracting the FPKM value of each tumor from the mean FPKM values of two non-tumor tissues.
DNA methylation analysis
DNA methylation status was examined using an Infinium HumanMethylation450 Bead Array (Illumina), as described previously (14) . β-values, which reflect the methylation level of an individual CpG site and range from 0.00 to 1.00, were used to evaluate methylation differences for each probe. To avoid any gender-specific methylation bias, all CpG sites on chromosomes X and Y were excluded from the analysis. In addition, to avoid attribution of polymorphisms at CpG sites, probes showing low call rates were also excluded, as described previously (14) . The methylation statuses of cases with and without TET2 mutations were compared by subtraction of the β-values of tumors (β-value of cancerous tissue subtracted from β-value of corresponding non-cancerous tissue). Loci with more (or less) methylation in TET2-mutated cases were defined by selection based on two thresholds: methylation difference (i.e. average of subtracted β-value in TET2-mutated cases -average of subtracted β-value in TET2-wild-type cases) > 0.3 or < −0.3, and P value calculated by t-test of average values < 0.01.
Gene ontology analysis
Functional enrichment analysis of genes hypermethylated in TET2-mutated tumors was performed by the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/).
Statistical analysis
Statistical analyses of differences in DNA methylation or RNA expression between cases with and without TET2 mutations were assessed by t-test or Mann-Whitney U test using GraphPad Prism 6.0 software (GraphPad Software). Values of P < 0.05 were considered significant.
Results
Patient characteristics
The clinicopathological characteristics of the 10 patients with TCs included in this study are summarized in Table 1 . The average age was 60.1 years (range: 41-77 years). Six patients were female and four were male. Among 10 patients, 9 received primary tumor resection; the remaining patient (TH13-015) received multiple regimens of chemotherapy before autopsy. Although 9 of 10 cases were diagnosed with squamous cell
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epithelial stromal interaction 1 FPKM fragments per kilobase of exon per million fragments mapped TC Thymic carcinoma carcinoma, 1 (TH13-003) was identified as undifferentiated carcinoma. Genomic DNA samples were extracted from pairs of cancerous and non-cancerous thymic tissue specimens from the 10 patients and subjected to whole exome sequencing. RNA samples from 10 cancerous and 3 non-cancerous tissue specimens were subjected to whole transcriptome sequencing.
Somatic mutation profiling
Somatic mutations, single-nucleotide variations and Indels, identified by exome sequencing in TCs are listed in Supplementary Table S1 , available at Carcinogenesis Online and the numbers of mutations, along with the mutation burden (number of mutations/Mb), defined by exome sequencing are presented in Table 1 . The average number of mutations (synonymous and non-synonymous) per sample was 45.1 (range, 11-83) ( Figure 1A ). Of note, the case (TH13-015) who received multiple regimens of chemotherapy before autopsy had the greatest number of mutations. Unsupervised hierarchical clustering of TC genome based on the mutational signatures identified two case groups ( Figure 1B ). The major group including 8 of 10 cases (e.g. TH14-001) was predominance for COSMIC signature 1 (clock-like) related to spontaneous deamination of 5-methylcytosine ( Figure 1C ), whereas the other group contained two cases (TH13-003 and TH13-013) predominant for COSMIC signature 6 (DNA mismatch repair deficiency) and COSMIC signature 5 (clock-like) ( Figure 1C ) (19) .
Consistent with a previous exome sequencing analysis of TCs from the patients of USA/Europe (4), mutations in cancer gene census genes, CYLD, TP53, HRAS, and RB1, were observed in TCs from Japanese patients (Figure 2 ). Mutations in TET2 and SETD2, which were found in a target sequencing study of TCs from patients of USA/Europe (5), were also observed in three and two Japanese cases, respectively, and the mutations were associated with focal copy number losses, as determined by SNP chip analysis. Deleterious mutations in the chromatin regulator genes, BRD7 and ASH1L, were also commonly detected; therefore, similar sets of cancer-related and chromatin regulator genes are mutated in TCs irrespective of patient ethnicity.
A previous report identified the BRD4-NUT fusion in USA/ European TCs (4); however, this fusion was not found in the Japanese cases. Alternatively, a novel in-frame MSI2-VEZF1 fusion was found in a single case (TH13-009) by RNA sequencing (Supplementary Table S2 and Figure S1 , available at Carcinogenesis Online). The MSI2-HOXA9 fusion is associated with chronic myeloid leukemia (15) , suggesting that it might also contribute to thymic carcinogenesis.
Epigenetic gene repression associated with TET2 mutation
The high frequency of TET2 mutations observed (3/10; 30%), in addition to the fact that the three mutations consisted of one deleterious and two recurrent (i.e. deposited in the COSMIC database) mutations, prompted us to examine the biological significance of these TET alterations. TET2 mutations cause aberrant hypermethylation of the genome, by impairment of DNA demethylation, mediated by conversion of 5-methylcytosine to 5-hydroxymethylcytosine, leading to reduced repression of genes subject to hypermethylation in acute myeloid leukemia (16) . Therefore, we explored the epigenetic changes associated with TET2 mutation in TCs by comparing the genome-wide methylation status of TET2 mutation-positive (n = 3) and mutation-negative (n = 7) cases. Whole methylome analysis indicated the presence of more hypermethylated loci in TET2 mutationpositive tumors than in negative tumors ( Figure 3A) . Among 454 probes with differential methylation between TET2 mutationpositive and TET2 mutation-negative cases, selected according to our criteria (as described in Materials and methods), 422 (93.0%), representing 332 genes, exhibited elevated methylation in TET2-mutated TCs compared with non-mutated tumors (red dots, Figure 3A ), whereas 32 probes (7.0%), representing 26 genes, showed the opposite effect (blue dots, Figure 3A) . Two genes, epithelial stromal interaction 1 (EPSTI1) (two probes; P = 1.58E-08 and 1.17E-07) and family with sequence similarity 110 member A (FAM110A) (P = 1.05E-07), were more significantly methylated after Bonferroni correction (P < 1.72E-07 [0.05/291 497 probe]) in TET2-mutated TCs than in non-mutated tumors. Next, we investigated the transcriptional changes associated with TET2 methylation in TCs by comparing gene expression between TET2 mutation-positive (n = 3) and mutation-negative (n = 5) cases. Among 454 probes, representing 332 genes showing differences in methylation between TET2 mutation-positive and mutation-negative cases (red dots, Figure 3A) , we evaluated the gene expression of 163 genes and expressed the data as the subtracted FPKM value ( Figure 3B ). Genes at hypermethylated loci tended to show lower expression in tumors with TET2 mutations than in those without these mutations (P < 0.0001, Mann-Whitney U test). DAVID gene annotation enrichment analysis indicated that hypermethylated genes in TET2-mutated TCs were enriched for those involved in sequence-specific DNA binding and chromosomal rearrangement (FDR < 0.05) ( Figure 3C and Supplementary  Table S3 , available at Carcinogenesis Online). EPSTI1, bone marrow stromal cell antigen 2 (BST2), CCR4-NOT transcription complex subunit 9 (CNOT9/RQCD1), microcephalin 1 (MCPH1), and HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5) were the top five genes with comparatively reduced expression in tumors with TET2 mutations, compared with those with wildtype TET2 ( Figure 3D and Supplementary Table S4, available at Carcinogenesis Online). Of note, EPSTI1 was the most prominent gene whose expression was suppressed by hypermethylation in TET2-mutated TCs. None of these genes showed somatic mutations and/or copy number loss; therefore, the observed reduced expression is likely to be caused by epigenetic differences.
Gene upregulation associated with focal copy number gain
To identify candidate oncogenes, we searched for genes within focal genome amplifications associated with elevated expression ( Table 2) . The KIT gene, activating mutations of which have previously been observed in TCs (6) , showed focal amplification with elevated expression in a single case (TH13-002). In addition, the chromosome 14q32.33 region, containing the AKT1 oncogene locus, was focally amplified in three cases (TH13-002, TH13-010 and TH14-001); however, elevated AKT1 expression was not observed in these cases, whereas elevated expression of another gene in this region, AHNAK2 [AHNAK (meaning giant in Hebrew) nucleoprotein 2], encoding a large submembrane protein (17) , was observed in two of the cases for which RNA could be analyzed (Supplementary Figure S2 , available at Carcinogenesis Online).
Discussion
Here, we describe genetic and epigenetic features of 10 Japanese TC cases. Mutational signatures represented by the trinucleotide mutational landscape have been examined in a variety of cancers to deduce mutagenic processes driving tumorigenesis, such as smoking, UV exposure and replication errors (18) . In the present study, COSMIC signature 1 (clock-like) was most predominant in TC, followed by COSMIC signature 6 (DNA mismatch repair deficiency) and COSMIC signature 5 (clock-like) (19) , suggesting that the accumulation of age-related mutation drives TC development. Our results are consistent with the fact that age is a major risk factor for TC development (20, 21) , although few specific etiological factors for this disease have been elucidated (22) . Somatic TET2, SETD2, CYLD, TP53 and RB1 mutations observed in our cases indicate that aberrations of tumor suppressor genes, as well as epigenetic regulator genes, play roles in the development of TC, irrespective of ethnicity (4, 5) . In addition, the lack of GTF2I mutations supports the published hypothesis that TC and thymoma can be distinguished by their genetic profiles (4) . Here, we focused on TET2 mutations, as the most frequent alterations observed, and revealed an epigenomic feature of TET2-mutated TCs; namely, hypermethylation of a set of genes involved in DNA binding and chromosomal rearrangements. In addition to EPSTI1, four genes, BST2, RQCD1, MCPH1 and HERC5, were identified as representative and showed reduced expression associated with hypermethylation. Hypermethylation of HERC5 associated with poor survival has been previously reported in non-small cell lung cancer (23) . To the best of our knowledge, the pathogenic significance of the other four genes in tumorigenesis has not been determined. Further studies of hypermethylated/downregulated genes will facilitate understanding of the biological and pathological features of TET2-mutated TCs.
Previous studies identified activating EGFR and KIT mutations and HER2 amplification in a small subset (<10 %) of TCs (6, 7) . Activating KIT mutations in TC are therapeutic targets for tyrosine kinase inhibitors, such as imatinib and sunitinib (3, 24, 25) . In this study, focal copy number gain of KIT associated with elevated expression was observed in a single case. An investigation of the prevalence of focal KIT amplification in TCs and their response to KIT-tyrosine kinase inhibitors would be worthwhile. The present study also identified AHNAK2 at chromosome 14q32.33 as a candidate oncogene when amplified. AHNAK2 functions in stress-induced FGF1 secretion, can stimulate angiogenesis and may contribute to tumorigenesis in this manner (17) . Studies of genetic and epigenetic aberrations in larger sets of TC samples from patients with a wider range of ethnicities will facilitate understanding of the etiological mechanisms underlying TC development and in the development of diagnostic and treatment strategies.
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